Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors.

Singh R, Fazal Z, Freemantle SJ, Spinella MJ.

Cancer Drug Resist. 2019;2(3):580-594. doi: 10.20517/cdr.2019.19. Epub 2019 Sep 19.

2.

The potential of retinoids for combination therapy of lung cancer: Updates and future directions.

Tripathi SK, Pandey K, Panda M, Spinella MJ, Rengasamy KR, Biswal BK.

Pharmacol Res. 2019 Sep;147:104331. doi: 10.1016/j.phrs.2019.104331. Epub 2019 Jun 26. Review.

PMID:
31254665
3.

Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors.

Singh R, Fazal Z, Corbet AK, Bikorimana E, Rodriguez JC, Khan EM, Shahid K, Freemantle SJ, Spinella MJ.

Cancers (Basel). 2019 Jun 8;11(6). pii: E796. doi: 10.3390/cancers11060796.

4.

Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Chovanec M, Taza F, Kalra M, Hahn N, Nephew KP, Spinella MJ, Albany C.

Target Oncol. 2018 Feb;13(1):49-60. doi: 10.1007/s11523-017-0546-x.

5.

G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.

Yim CY, Bikorimana E, Khan E, Warzecha JM, Shin L, Rodriguez J, Dmitrovsky E, Freemantle SJ, Spinella MJ.

Cell Cycle. 2017;16(21):2146-2155. doi: 10.1080/15384101.2017.1371884. Epub 2017 Sep 14.

6.

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.

Albany C, Hever-Jardine MP, von Herrmann KM, Yim CY, Tam J, Warzecha JM, Shin L, Bock SE, Curran BS, Chaudhry AS, Kim F, Sandusky GE, Taverna P, Freemantle SJ, Christensen BC, Einhorn LH, Spinella MJ.

Oncotarget. 2017 Jan 10;8(2):2949-2959. doi: 10.18632/oncotarget.13811.

7.

Epigenetic Targeting of Platinum Resistant Testicular Cancer.

Sonnenburg D, Spinella MJ, Albany C.

Curr Cancer Drug Targets. 2016;16(9):789-795. Review.

8.

G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program.

Yim CY, Sekula DJ, Hever-Jardine MP, Liu X, Warzecha JM, Tam J, Freemantle SJ, Dmitrovsky E, Spinella MJ.

Cancer Res. 2016 Mar 1;76(5):1204-13. doi: 10.1158/0008-5472.CAN-15-2265. Epub 2016 Feb 2.

9.

All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched.

Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E.

Cancer Biol Ther. 2014 Apr;15(4):463-72. doi: 10.4161/cbt.27821. Epub 2014 Feb 4.

10.

Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives.

Yim CY, Mao P, Spinella MJ.

AAPS J. 2014 Mar;16(2):281-8. doi: 10.1208/s12248-014-9562-2. Epub 2014 Jan 16. Review.

11.

Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma.

Mao P, Hever-Jardine MP, Rahme GJ, Yang E, Tam J, Kodali A, Biswal B, Fadul CE, Gaur A, Israel MA, Spinella MJ.

PLoS One. 2013 Nov 28;8(11):e81803. doi: 10.1371/journal.pone.0081803. eCollection 2013.

12.

Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation.

Biswal BK, Beyrouthy MJ, Hever-Jardine MP, Armstrong D, Tomlinson CR, Christensen BC, Marsit CJ, Spinella MJ.

PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.

13.

Modulation of clock gene expression by the transcriptional coregulator receptor interacting protein 140 (RIP140).

Poliandri AH, Gamsby JJ, Christian M, Spinella MJ, Loros JJ, Dunlap JC, Parker MG.

J Biol Rhythms. 2011 Jun;26(3):187-99. doi: 10.1177/0748730411401579.

14.

Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.

Mao P, Hever MP, Niemaszyk LM, Haghkerdar JM, Yanco EG, Desai D, Beyrouthy MJ, Kerley-Hamilton JS, Freemantle SJ, Spinella MJ.

J Biol Chem. 2011 Jun 3;286(22):19381-91. doi: 10.1074/jbc.M111.218040. Epub 2011 Apr 13.

15.

High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.

Beyrouthy MJ, Garner KM, Hever MP, Freemantle SJ, Eastman A, Dmitrovsky E, Spinella MJ.

Cancer Res. 2009 Dec 15;69(24):9360-6. doi: 10.1158/0008-5472.CAN-09-1490.

16.

Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting.

Snow GE, Kasper AC, Busch AM, Schwarz E, Ewings KE, Bee T, Spinella MJ, Dmitrovsky E, Freemantle SJ.

BMC Cancer. 2009 Oct 29;9:383. doi: 10.1186/1471-2407-9-383.

17.

Retinoic acid mediates long-paced oscillations in retinoid receptor activity: evidence for a potential role for RIP140.

Heim KC, Gamsby JJ, Hever MP, Freemantle SJ, Loros JJ, Dunlap JC, Spinella MJ.

PLoS One. 2009 Oct 28;4(10):e7639. doi: 10.1371/journal.pone.0007639.

18.

Selective repression of retinoic acid target genes by RIP140 during induced tumor cell differentiation of pluripotent human embryonal carcinoma cells.

Heim KC, White KA, Deng D, Tomlinson CR, Moore JH, Freemantle SJ, Spinella MJ.

Mol Cancer. 2007 Sep 19;6:57.

19.

The direct p53 target gene, FLJ11259/DRAM, is a member of a novel family of transmembrane proteins.

Kerley-Hamilton JS, Pike AM, Hutchinson JA, Freemantle SJ, Spinella MJ.

Biochim Biophys Acta. 2007 Apr;1769(4):209-19. Epub 2007 Feb 22.

20.

Repression of cyclin D1 as a target for germ cell tumors.

Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Krizan KA, Kelley MR, Hattab EM, Memoli VA, Black CC, Spinella MJ, Dmitrovsky E.

Int J Oncol. 2007 Feb;30(2):333-40.

PMID:
17203214
21.

Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Giuliano CJ, Freemantle SJ, Spinella MJ.

Curr Cancer Ther Rev. 2006 Aug 1;2(3):255-270.

22.

Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity.

Giuliano CJ, Kerley-Hamilton JS, Bee T, Freemantle SJ, Manickaratnam R, Dmitrovsky E, Spinella MJ.

Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. Epub 2005 Sep 1.

PMID:
16168501
23.

A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma.

Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J, Spinella MJ.

Oncogene. 2005 Sep 8;24(40):6090-100.

PMID:
15940259
25.

Limiting effects of RIP140 in estrogen signaling: potential mediation of anti-estrogenic effects of retinoic acid.

White KA, Yore MM, Deng D, Spinella MJ.

J Biol Chem. 2005 Mar 4;280(9):7829-35. Epub 2005 Jan 4.

26.

Retinoids in cancer therapy and chemoprevention: promise meets resistance.

Freemantle SJ, Spinella MJ, Dmitrovsky E.

Oncogene. 2003 Oct 20;22(47):7305-15. Review.

PMID:
14576840
27.

Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140.

White KA, Yore MM, Warburton SL, Vaseva AV, Rieder E, Freemantle SJ, Spinella MJ.

J Biol Chem. 2003 Nov 7;278(45):43889-92. Epub 2003 Sep 22.

28.

Retinoid target gene activation during induced tumor cell differentiation: human embryonal carcinoma as a model.

Spinella MJ, Kerley JS, White KA, Curtin JC.

J Nutr. 2003 Jan;133(1):273S-276S. Review.

PMID:
12514308
29.

Characterization and tissue-specific expression of human GSK-3-binding proteins FRAT1 and FRAT2.

Freemantle SJ, Portland HB, Ewings K, Dmitrovsky F, DiPetrillo K, Spinella MJ, Dmitrovsky E.

Gene. 2002 May 29;291(1-2):17-27.

PMID:
12095675
30.
31.

Cyclin proteolysis as a retinoid cancer prevention mechanism.

Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E.

Ann N Y Acad Sci. 2001 Dec;952:13-22. Review.

PMID:
11795432
32.

Transcriptional activation of the nuclear receptor corepressor RIP140 by retinoic acid: a potential negative-feedback regulatory mechanism.

Kerley JS, Olsen SL, Freemantle SJ, Spinella MJ.

Biochem Biophys Res Commun. 2001 Jul 27;285(4):969-75.

PMID:
11467847
33.

Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function.

Curtin JC, Dragnev KH, Sekula D, Christie AJ, Dmitrovsky E, Spinella MJ.

Oncogene. 2001 May 3;20(20):2559-69.

34.

Aerosolized delivery and lung cancer prevention: pre-clinical models show promise.

Spinella MJ, Dmitrovsky E.

Clin Cancer Res. 2000 Aug;6(8):2963-4. No abstract available.

35.

Aberrant retinoid signaling and breast cancer: the view from outside the nucleus.

Spinella MJ, Dmitrovsky E.

J Natl Cancer Inst. 2000 Mar 15;92(6):438-40. No abstract available.

PMID:
10716952
36.
37.

Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation.

Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E.

J Biol Chem. 1999 Jul 30;274(31):22013-8.

38.

A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.

Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K, Sporn MB.

Cancer Res. 1999 Jan 15;59(2):336-41.

39.

FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas.

Maerz WJ, Baselga J, Reuter VE, Mellado B, Myers ML, Bosl GJ, Spinella MJ, Dmitrovsky E.

Oncogene. 1998 Aug 13;17(6):761-7.

40.

Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells.

Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS, Dmitrovsky E.

Oncogene. 1998 Jul 2;16(26):3471-80.

41.

Organization of the murine reduced folate carrier gene and identification of variant splice forms.

Brigle KE, Spinella MJ, Sierra EE, Goldman ID.

Biochim Biophys Acta. 1997 Aug 7;1353(2):191-8.

PMID:
9294013
42.
43.
45.

Molecular cloning of murine folylpoly-gamma-glutamate synthetase.

Spinella MJ, Brigle KE, GoldmanD.

Biochim Biophys Acta. 1996 Feb 7;1305(1-2):11-4.

PMID:
8605241
46.

Comparison of transport properties of the reduced folate carrier and folate receptor in murine L1210 leukemia cells.

Sierra EE, Brigle KE, Spinella MJ, Goldman ID.

Biochem Pharmacol. 1995 Oct 12;50(8):1287-94.

PMID:
7488246
47.

Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line.

Brigle KE, Spinella MJ, Sierra EE, Goldman ID.

J Biol Chem. 1995 Sep 29;270(39):22974-9.

48.

Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.

Kranz DM, Patrick TA, Brigle KE, Spinella MJ, Roy EJ.

Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9057-61.

49.
50.

Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells.

Brigle KE, Spinella MJ, Westin EH, Goldman ID.

Biochem Pharmacol. 1994 Jan 20;47(2):337-45.

PMID:
8304978

Supplemental Content

Loading ...
Support Center